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Beryllium is a strategic metal with unique
physicochemical properties. It is light weight,
nonsparking, noncorrosive, and stiffer than
steel and has a high melting temperature. The
dissolution half-life for beryllium particles
ranges from tens to hundreds of days, depend-
ing on its chemical form (Hoover et al. 1988).
The metal and its oxides and alloys are indis-
pensable in the nuclear, aerospace, ceramics,
and telecommunications industries. Its uses
have expanded to include tools for emergency
response teams, computers, dental implants,
specialty golf clubs, and bicycle frames.
Exposure to beryllium causes an incurable
occupational lung disease, chronic beryllium
disease (CBD), in approximately 3–5% of
exposed workers (Henneberger et al. 2001;
Kreiss et al. 1996, 1997; Newman et al. 2001;
Schuler et al. 2002). Estimates of the current
exposed worker population vary from
100,000 to 800,000 individuals (Cullen et al.
1986); however, decommissioning of beryl-
lium-contaminated buildings at nuclear
defense sites over the next 10 years may
increase these numbers signiﬁcantly.
CBD is a progressive granulomatous lung
disease that is characterized by an MHC
(major histocompatibility complex) class
II–restricted, T-helper 1, CD4+ lymphocyto-
sis (Epstein et al. 1982; Saltini et al. 1989).
Immunologic sensitization to beryllium can
be detected in peripheral blood cells by the
beryllium-stimulated lymphocyte prolifera-
tion test (BeLPT). A positive peripheral
blood BeLPT frequently precedes a positive
bronchoalveolar lavage (BAL) cell BeLPT
(Henneberger et al. 2001; Kreiss et al. 1993a,
1993b, 1996, 1997). A positive BAL cell
BeLPT and histologic evidence of noncaseat-
ing granulomas on transbronchial lung biopsy
support the diagnosis of disease (Newman et
al. 1989).
Over the last decade, the prevalence of dis-
ease has not declined despite enactment of
exposure limits by the Atomic Energy
Commission and the implementation of
improved control technology designed to elim-
inate respiratory exposure (Eisenbud 1982).
Industrial hygiene studies demonstrated that
disease prevalence correlates with beryllium
ultrafine particle counts, not with beryllium
mass measurements (Martyny et al. 2000;
McCawley et al. 2001). Epidemiologic analy-
ses showed that beryllium workers with the
highest rates of disease are those involved in
machining and grinding, tasks that generate
significant amounts of dust (Kreiss et al.
1996, 1997). These workers had significant
respiratory protection and engineering con-
trols in their work environments, but no skin
protection. Furthermore, cutaneous sensitiza-
tion to beryllium is consistent with the clinical
observation that beryllium-speciﬁc peripheral
blood lymphocyte proliferation often precedes
a positive pulmonary response, yet skin was
not considered a route of exposure for worker
sensitization. In this article we provide evi-
dence that skin exposure may contribute to
the persistence of beryllium sensitization in
the workplace.
Due to the particulate nature of most
exposures, the barrier properties of the skin,
the low solubility of the metal and its alloys,
and localization of disease in the lung, skin
exposure to beryllium has not been considered
hazardous. The external layer of the skin, the
stratum corneum, is considered a mechanically
strong and resilient structure that can with-
stand physical strain and stress. It is considered
an effective barrier essential to the protection
of the internal milieu from the external envi-
ronment; however, there are several reports of
particle penetration into the stratum corneum
and hair follicles, and a report of increased tita-
nium in the epidermis and dermis following
the application of sunscreens containing tita-
nium dioxide (Lademann et al. 1999; Tan et
al. 1996). Microparticles have also been iden-
tiﬁed in the lymph nodes (LNs) and dermis of
individuals in African rift valleys who walked
barefoot and developed elephantiasis of the
feet and legs (Blundell et al. 1989; Corachan
et al. 1988). Using the guinea pig model, sev-
eral researchers from 1950 through the 1980s
used cutaneous application of beryllium salts
and metal to conﬁrm beryllium induction of a
delayed-type hypersensitivity (DTH) response
(Alekseeva 1965; Curtis 1951; Denham and
Hall 1988; Jones and Amos 1974; Krivanek
and Reeves 1972). Interestingly, only a subset
of guinea pigs responded to beryllium in each
study, and conclusions were sometimes based
on data obtained from two or three animals
(Alekseeva 1965; Krivanek and Reeves 1972).
Attempts to develop a murine model of
chronic disease were largely unsuccessful,
although a single article reports the develop-
ment of a beryllium DTH and granulomas in
A/J mice (Huang et al. 1992). Although not
widely considered to be a safe diagnostic pro-
cedure, several studies have evaluated elicita-
tion of the cutaneous beryllium DTH
response in beryllium-sensitized and CBD
patients using the skin patch test (Bobka et al.
1997; Curtis 1951; Fontenot et al. 2002).
These multidisciplinary observations led us
to propose skin exposure to beryllium particu-
lates as a route of beryllium sensitization.
Speciﬁcally, we hypothesized that ﬁne particles
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Chronic beryllium disease is an occupational lung disease that begins as a cell-mediated immune
response to beryllium. Although respiratory and engineering controls have signiﬁcantly decreased
occupational beryllium exposures over the last decade, the rate of beryllium sensitization has not
declined. We hypothesized that skin exposure to beryllium particles would provide an alternative
route for sensitization to this metal. We employed optical scanning laser confocal microscopy and
size-selected fluorospheres to demonstrate that 0.5- and 1.0-µm particles, in conjunction with
motion, as at the wrist, penetrate the stratum corneum of human skin and reach the epidermis and,
occasionally, the dermis. The cutaneous immune response to chemical sensitizers is initiated in the
skin, matures in the local lymph node (LN), and releases hapten-speciﬁc T cells into the peripheral
blood. Topical application of beryllium to C3H mice generated beryllium-speciﬁc sensitization that
was documented by peripheral blood and LN beryllium lymphocyte proliferation tests (BeLPT)
and by changes in LN T-cell activation markers, increased expression of CD44, and decreased
CD62L. In a sensitization–challenge treatment paradigm, epicutaneous beryllium increased murine
ear thickness following chemical challenge. These data are consistent with development of a hap-
ten-speciﬁc, cell-mediated immune response following topical application of beryllium and suggest
a mechanistic link between the persistent rate of beryllium worker sensitization and skin exposure
to ﬁne and ultraﬁne beryllium particles. Key words: beryllium, exposure, particle, sensitization, skin.
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reach the immunologically active epidermis,
and that ﬂexing motion, as at the wrist, pro-
vides the kinetic energy necessary to move par-
ticles into the skin. This motion would be
analogous to the pressure applied by walking
barefoot or to the motion associated with
machining and grinding. For these studies, we
evaluated ﬂuorescent dextran particle penetra-
tion of human skin ex vivo with laser scanning
confocal microscopy, and cutaneous sensitiza-
tion of mice using beryllium salts and beryl-
lium oxide. We tested antigen speciﬁcity with
a murine beryllium-speciﬁc lymphocyte prolif-
eration assay, hapten-induced changes in LN
cell activation markers with flow cytometry,
and a well-established measurement of cuta-
neous sensitization, elicitation of the ear-
swelling response.
Materials and Methods
Tissue handling parameters. Human skin,
300–400 µm thick, was obtained from the
back or the thigh (Center for Organ Recovery
and Education, Pittsburgh, PA) and stored on
mesh in a 100-mm petri dish with the surface
of the skin at the air–liquid interface. Tissue
was stored in RPMI 1640 medium (Irvine
Scientiﬁc, Santa Ana, CA) containing 25 mM
HEPES, 2 mM L-glutamine, 10% (vol/vol)
fetal bovine serum (FBS; Gibco BRL,
Gaithersburg, MD), 100 U/mL penicillin, and
100 µg/mL streptomycin at 4°C. Pilot studies
verifying the health of the tissue samples
revealed minimal release of the cytoplasmic
enzyme lactate dehydrogenase into the medium
for 5 days after arrival, and tissues were used
within 24–48 hr (Wester et al. 1998).
Integrity of the stratum corneum was veri-
ﬁed immediately before each experiment using
the NOVA Dermaphase Meter, model 9008
(NOVA Technology Corp., Gloucester, MA),
which measures the skin surface electrical
impedance as the ratio of the current to the
potential on an electrically charged isolated
conductor. A cutoff of 300 units was deter-
mined by a pilot study and previous published
literature (Newman and Seitz 1990; Okah et
al. 1995). All skin tissues in the study had
capacitance measurements of ≤ 300 units, sig-
nifying that the stratum corneum was intact.
Additionally, systematic examination of each
tissue sample by microscopy conﬁrmed visu-
ally the integrity of the stratum corneum.
Humidity during experiments ranged
between 56% and 70%, and room tempera-
ture was maintained between 21°C and 23°C.
Flexing procedure. Skin, 1.5 × 0.5 inches,
was fixed to the flexing device with double-
sided tape and ﬂexed at 45°, 20 ﬂexes/minute,
or left ﬂat, for 15, 30, or 60 min. One hun-
dred microliters of a 25% solid solution of
0.5-, 1-, 2-, or 4-µm–diameter fluorescein
isothiocyanate (FITC)–conjugated dextran
beads were applied to the surface of the tissue,
directly over the flex area. Control tissues,
obtained from matching skin samples,
received the same application of beads under
the same physical conditions as the ﬂexed tis-
sues, but were left flat and not flexed. After
experimental manipulation, skin was rinsed in
1× phosphate-buffered saline (PBS), fixed
overnight in 10% buffered formalin, and ﬂash
frozen in liquid nitrogen. Twenty micrometer
cross-sections were cut, stained with toluidine
blue to visualize morphology, and cover-
slipped using a glycerine gel. Eight skin sam-
ples were tested at all time points under ﬂexed
and ﬂat conditions. Additional samples were
tested under ﬂexed conditions only.
Confocal microscopy. We evaluated pene-
tration of beads into the skin 20-µm–thick
cross sections at 1-µm intervals by laser scan-
ning confocal microscopy. Optical scans used
in the data analysis were obtained from the
center of the tissues, between 5 and 15 µm
only. Confocal images were recorded using a
Sarastro 2000 laser scanning confocal micro-
scope (Molecular Dynamics, Inc., Sunnyvale,
CA) fitted with an argon-ion laser. Using a
40× objective, images with a ﬁeld size of 512
× 512 µm were generated by collecting 25
sections 1.0 µm thick along the z-axis.
Emission spectra > 535 nm were diverted to
one photodetector and used to image ﬂuores-
cent beads. Transmitted light was simultane-
ously passed to a separate optical path and
provided images of skin tissue. Images of skin
tissue and ﬂuorescent beads were combined to
reveal the position of beads among skin struc-
tures. All scans were recorded at photomulti-
plier tube settings of 480–540, a pinhole
aperture setting of 50 µm, and a laser voltage
setting of 20 mW.
Scanning electron microscopy. To prepare
samples for scanning electron microscopy,
ﬂexed or ﬂat tissue samples were rinsed in 1×
PBS, gently patted dry, and then subjected to
repeat applications of D-Squame tape
(Cuderm Corp., Dallas, TX). A fresh piece of
D-Squame tape was used for each tape strip.
Removal of 6–7 µm of the stratum corneum
by 30 tape strips using D-Squame tape and
significant increases in transepidermal water
loss after 30 tape strips have been docu-
mented (Dreher et al. 1998; van der Molen et
al. 1997). Tissues were ﬁxed in 10% neutral
buffered formalin, dehydrated with ethanol,
and dried with hexamethyldisilazane. The
samples were mounted on aluminum stubs
and coated with gold/palladium. We used a
JEOL 6400 scanning electron microscope
(JEOL, Tokyo, Japan) at 20 keV for imaging
the samples.
Murine care and treatment. C3H/HeJ or
C3H/HeOuJ mice, 5–9 weeks of age, were
housed (ﬁve per cage) according to American
Association for Accreditation of Laboratory
Animal Care-approved guidelines (National
Research Council 1996), and the protocols for
these studies were approved by the National
Institute for Occupational Safety and Health
Animal Care and Use Committee. These mice
have the putative beryllium presentation allele
Iak and differ only at the CD14 locus
(mutated in the HeJ mice), and pilot studies
in our laboratory showed them to be equally
responsive to beryllium. We first confirmed
beryllium sensitization in HeJ mice because of
their historical use, and then translated our
studies to the OuJ mice to avoid any potential
complication due to the CD14 mutation.
Lymphocyte proliferation studies. Twenty-
five microliters of a (4:1) mixture of
acetone:olive oil (AOO) or a mixture of 0.5 M
beryllium sulfate (BeSO4; 99.99% pure;
Sigma, St. Louis, MO) dissolved in AOO was
pipetted onto the dorsum of the ears of the
mice for 3 consecutive days each week for 2
weeks. This application paradigm was deter-
mined by pilot studies in our laboratory that
evaluated 0.01–0.5 M BeSO4, the number of
applications of chemical, and the optimal time
point following application at which to obtain
the cells. Forty-eight hours after the final
application of chemical, mice (10 per treat-
ment group) were euthanized by CO2 inhala-
tion. Blood was collected immediately by
cardiac puncture, and peripheral blood
mononuclear cells (PBMCs) were isolated
against a ficoll-hypaque gradient and resus-
pended in complete media containing 90%
(vol/vol) RPMI 1640, 10% FBS, 100 U/mL
penicillin, and 100 µg/mL streptomycin
(Sigma). Right and left auricular LNs were
surgically removed. LN cells were dissociated
sequentially through 400-µm and 200-µm
nylon meshes, rinsed in RPMI 1640, and
resuspended in complete media (Kimber and
Dearman 1991). Viability (> 90% for all stud-
ies) was determined by trypan blue exclusion.
To obtain enough cells for a single prolifera-
tion experiment, we pooled cells from all mice
in a treatment group. 
Cells were cultured at 1 × 106 cells/mL in
triplicate or quadruplicate according to the
established BeLPT protocol (Rossman et al.
1988). Culture conditions included stimula-
tion with 10 µg/mL phytohemagglutinin
(PHA), 100 µM BeSO4, or 50 µM Al2SO4,
and cells were harvested at designated time
points. Isotopic decay [disintegrations per
minute (dpm)] for each experimental condi-
tion was averaged and is presented as mean ±
SEM. All proliferation experiments were
repeated three to ﬁve times.
Flow cytometric analysis. We pipetted 25
µL 0.5 M BeSO4 in dibutylphthalate
(BeSO4/DBPT; 1:1) or the positive control,
0.25% 2,4-dinitrofluorobenzene (DNFB;
Sigma) in 4:1 AOO, onto the dorsum of the
ears for 3 consecutive days. Auricular LN
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formed flow cytometric analysis of surface
phenotype by two- or three-color staining
using FITC-, phycoerythrin-, and allophyco-
cyanin-conjugated rat or hamster anti-mouse
monoclonal antibodies. LN cells were stained
with monoclonal antibodies against CD3,
CD44, and CD62L (BD PharMingen, San
Diego, CA). Nonspeciﬁc binding was assessed
with isotype antibodies directed against
immunoglobulins IgG1, IgG2a, and IgG2b.
We determined the percentage of nonviable
cells by propidium iodide uptake. Samples were
analyzed in duplicate using a FACScalibur ﬂow
cytometer and CellQuest software (both from
BD Biosciences, Franklin Lakes, NJ).
For beryllium oxide particle induction of
sensitization, mice were shaved on the back
and depilated with Nair (Carter Products,
New York, NY), in a 1.5 × 3 cm area, 24 hr
before chemical treatment. BeO particles
(99.98% pure; Sigma) were suspended in
petrolatum (1 mg/g). This suspension was
painted on the back, and the area was covered
with Blenderm surgical tape (3M Health
Care, St. Paul, MN). Tape was removed after
24–30 hr. The average amount of beryllium
applied to each mouse was 70 µg/Blenderm
tape (range, 59–100 µg/sample), and the
average amount of beryllium in the ﬂank skin
7 days after application of the BeO/petrola-
tum was 1.2 µg beryllium/g skin tissue (range,
0.8–3.1 µg/g skin tissue). Mice received
25 µL 0.5 M BeSO4/DBPT on the ear on day
7. Flow cytometric analysis was performed 48
hr after challenge.
Ear swelling analysis. To determine the
effects of beryllium on ear thickness, we pipet-
ted 100 µL 0.5 M BeSO4/DBPT onto the
backs of mice on days 1 and 2, or we painted
BeO in petrolatum onto the backs and covered
the area with dermal tape for 30 hr. On day 7,
all mice were challenged on the ear with 25 µL
0.5 M BeSO4/DBPT. We measured ear thick-
ness with a digital micrometer at 24, 48, and
72 hr postchallenge for BeSO4 sensitization
and at 24 and 48 hr postchallenge for BeO
sensitization. Measurements for each treatment
group are presented as mean ± SEM.
Statistical analysis. Signiﬁcant differences
between treated and untreated groups were
determined by analysis of variance for cell pro-
liferation studies and by the t-test for flow
cytometric analysis. Analyses of ear swelling
data were conducted using PROC MIXED
and LSMEANS software (SAS Institute, Cary,
NC). Means and standard deviations were cal-
culated and compared using PROC MIXED
and adjusted for the covariate, initial ear thick-
ness. The LSMEANS option was used for cal-
culating means of treatment groups and for
adjustment of unequal sample sizes among
treatment groups. Statistical signiﬁcance was
deﬁned as p < 0.05.
Results
Fluorescent bead penetration of intact skin
samples. The particulate BeO is the primary
form of occupational exposure, and its half-life
is tens to hundreds of days. For a material with
a protracted dissolution half-life to provide a
concentration of beryllium in the epidermis
sufficient to activate cutaneous immunity,
BeO particles would have to colocalize with
the Langerhans cell, the predominant antigen-
presenting cell in the epidermis. Therefore, we
hypothesized that beryllium particles would
enter the epidermis to activate the cutaneous
immune response and that ﬂexing motion, as
at the wrist, would provide the energy neces-
sary for particle penetration of the stratum
corneum. To test this hypothesis, we exam-
ined particle penetration in skin samples that
were subjected to repeated 45° ﬂexure, 20 ﬂex-
ures per minute, and control tissues taken
from the same skin sample as the experimental
tissues but not ﬂexed. Penetration of ﬂuoros-
pheres into the skin was evaluated in 20-µm–
thick cross sections by laser scanning confocal
microscopy. The principal anatomical features
in a cross section, the stratum corneum, epi-
dermis, and dermis, are shown in Figure 1A,
and in side view in Figure 1B. Optical scans
were acquired at 1-µm intervals, and data were
obtained from the center of the tissues,
between 5 and 15 µm only. The area for data
collection is indicated by the yellow arrow in
Figure 1C. One-micrometer red ﬂuorospheres
are clearly visible in the stratum corneum and
epidermis after the 30-min application of
beads and flexing motion (blue arrows,
Figure 2A), and in the stratum corneum, epi-
dermis, and dermis at 60 min (all arrows,
Figure 2B). Occasional clusters of fluoros-
pheres were observed in the epidermis and the
dermis (yellow arrow, Figure 2B). To test the
relationship of particle size to penetration, we
also evaluated 0.5-, 2-, and 4-µm spheres. We
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Figure 1. Confocal microscopic imaging of human skin. (A) Following the flexing procedure (see “Materials and Methods” for details), optical scans were
obtained at 1-µm intervals through a 20-µm–thick tissue section. (B) A three-dimensional image of the cross section of tissue shown in (A) reconstructed by
Voxelview software, version 2.5.4 (Vital Images Inc., Minneapolis, MN) from the optical scans obtained for each sample. (C) Data were obtained from the center
of the tissue section as designated by the yellow arrow.
Article | Tinkle et al.observed penetration of 0.5-µm beads (Figure
2C) in addition to the 1-µm beads, and exclu-
sion of 2- and 4-µm beads (Figure 2D).
A summary of all data in this study
revealed that 0.5- and 1-µm beads penetrated
into the epidermis in 2 of 11 skin samples
(18%) ﬂexed for 15 min, in 5 of 12 samples
(41%) ﬂexed for 30 min, and in 9 of 16 sam-
ples (56%) ﬂexed for 60 min. Penetration into
the dermis occurred in two samples after ﬂex-
ing 60 min. The ﬂuorospheres that penetrated
through the stratum corneum represent only a
small percentage of the applied beads, and the
pattern of penetration was random. In contrast
to skin samples with intact stratum corneum,
discontinuous stratum corneum permitted
entry of a bolus of beads directly under the tear
(Figure 2E). No particle penetration was
observed in nonﬂexed tissues at any time point.
We repeated this study by combining tape
stripping of bead-exposed, flexed skin with
scanning electron microscopy (Figure 3).
Although the technique does not permit the
more precise tissue localization possible with
the laser scanning confocal procedure, we
observed beads in the skin after no tape strip-
ping (Figure 3A) and tape stripping 10 times
(Figure 3B) and 20 times (Figure 3C), to an
approximate depth of 6–7 µm into the stratum
corneum.
Cutaneous sensitization by beryllium salts.
We next asked if cutaneous application of
beryllium would initiate a beryllium-speciﬁc,
cell-mediated immune response in mice. Most
attempts to develop a CBD mouse model
employed multiple subcutaneous or intrader-
mal injections of BeSO4 for 2–6 weeks, fol-
lowed by a single intratracheal instillation, or
nose-only inhalation, of beryllium salts or res-
pirable beryllium particulates (Finch et al.
1998; Huang et al. 1992). From these expo-
sures, C3H/HeJ and A/J mice, but not BALB/c
or C57BL/6 mice, developed T-cell alveolitis,
and a subset of these mice developed sponta-
neously resolving pulmonary microgranulomas.
Beryllium-speciﬁc lymphocyte proliferation fol-
lowing the epicutaneous administration of
beryllium salts was not evaluated. Therefore, we
applied 50 µL 0.5 M BeSO4 dissolved in AOO
vehicle, or vehicle only, to the dorsal side of the
ear for 3 consecutive days per week for 2
weeks. We obtained auricular LN cells and
PBMC for each exposure group 48 hr after the
ﬁnal application of chemical, and the lympho-
proliferative response was measured by tritiated
thymidine incorporation at designated time
points. We conﬁrmed the proliferative ability
of the cell preparations with the mitogen PHA
and beryllium specificity with beryllium and
aluminum salts.
Evaluating the beryllium responsive
C3H/HeJ mice, we measured a 34.8-fold
beryllium-stimulated increase in auricular LN
cell proliferation at 48 hr (BeSO4-stimulated
cells vs. unstimulated cells: 29,691 ± 6,916
dpm vs. 517 ± 62 dpm, mean ± SEM;
p < 0.01; Figure 4) and a 30.7-fold increase in
PBMC proliferation at 120 hr (BeSO4-stimu-
lated cells vs. unstimulated cells: 51,342 ±
16,135 dpm vs. 1,673 ± 385 dpm; p < 0.03;
Figure 5). Beryllium salts did not stimulate LN
cell or PBMC proliferation in cells harvested
from mice treated with vehicle only. In both
treatment groups, the PHA response peaked at
24 hr in LN cells preparations and at 48 hr in
PBMC. BAL cells taken from beryllium skin-
sensitized mice produced no beryllium-speciﬁc
proliferation (data not shown).
Lymph node T-lymphocyte activation in
beryllium-sensitized mice. Expression of
CD44, a membrane glycoprotein involved in
cell adhesion and extravasation, is up-regu-
lated on activated and memory T cells.
CD62L, or L-selectin, is expressed on the
majority of B and T lymphocytes, and its
expression is rapidly lost upon T-cell activa-
tion. We next asked if cutaneous beryllium,
the salt solution and the oxide particles, could
induce LN T-lymphocyte activation, as mea-
sured by changes in CD44 and CD62L
expression. The well-studied skin sensitizer
DNFB served as the positive control. In the
ﬁrst series of experiments, BeSO4 or the con-
trol chemicals were applied to the dorsum of
the ears daily for 3 days, and auricular LNs
were harvested 48 hr later. In beryllium-
treated mice, we measured a 13% increase in
CD44+ LN cells (p < 0.008), an increase that
closely matched CD44 expression on LN cells
derived from DNFB-treated mice (p < 0.008;
Figure 6). In contrast, the percentage of
CD3+ LN cells expressing CD62L decreased
approximately 12% for BeSO4- (p < 0.008)
and DNFB-treated mice (p < 0.01).
Because of the difficulty applying
BeO/petrolatum under an occlusive patch to
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Figure 2. Confocal microscopic images of skin containing FITC-conjugated dextran beads (red). Images pre-
sented were obtained from the center of the tissue cross section at a depth of 10 µm. (A) One-micrometer
beads were observed at the stratum corneum–epidermal interface and in the epidermis following 30 min
of flexure blue arrows). (B) One-micrometer beads were observed at the stratum corneum–epidermal
interface and in the epidermis after 30 min of flexure, and in the epidermis and dermis after 60 min (all
arrows); beads were found randomly distributed in the tissue, and occasional clusters of beads were
identiﬁed (yellow arrows). (C) Beads (0.5-µm; blue arrows) were present in the epidermis after 30 min. (D)
Four-micrometer beads remained on the surface of the skin (tissue depth 13 µm). (E) Discontinuous stra-
tum corneum permitted entry of a bolus of 0.5-µm beads into the skin directly under the tear (blue arrow).
Bar = 10 µm for A–E.
Article | Skin exposure to beryllium induces sensitizationthe dorsum of the ears, we tested BeO in a sen-
sitization-challenge paradigm. To induce sensi-
tization, BeO/petrolatum was applied to the
back for 24–30 hr, and 6 days later, mice
received one treatment of beryllium salts on the
ear. A single application of BeSO4 to the ear
did not change the percentage of LN cells
expressing CD44/CD62L as demonstrated by
the DBPT/BeSO4-treated mice (p > 0.05;
Figure 6B). Mice treated with BeO on the back
before application of BeSO4 on the ear dis-
played a 10% increase in CD44+ LN cells (p <
0.006) and a 20% decrease in CD62L+/CD3+
cells (p < 0.001).
Parameters of cutaneous sensitization. To
evaluate elicitation of cutaneous sensitization,
we tested the skin antigen recall response, as
measured by increased ear thickness. We
tested the irritant/inﬂammatory properties of
beryllium salts with a single application of this
solution on the ear (DBPT/BeSO4-treated
mice) and, compared to mice receiving vehicle
on the ear (BeSO4/DBPT-treated mice), we
measured no signiﬁcant increase in ear thick-
ness at any time point (Figure 7). In contrast,
sensitization and challenge with beryllium salts
(BeSO4/BeSO4-treated mice) increased ear
thickness 25–30% at 24 and 48 hr (p < 0.04).
Mice receiving epicutaneous BeO and chal-
lenged once on the ear with the salts
(BeO/BeSO4-treated mice) displayed a 30%
increase at 24 hr that remained elevated signiﬁ-
cantly at 48 hr (p < 0.04). Because a single
application of beryllium to the ear does not
increase ear thickness unless preceded by beryl-
lium sensitization on the back, these data illus-
trate that BeO particles induced sensitization
in the BeO/BeSO4-treated mice, analogous to
the increase measured for BeSO4/BeSO4-
treated mice.
Discussion
The lung is the primary location for develop-
ment of noncaseating granulomas in beryl-
lium disease, and respiratory protection and
engineering controls, not skin protection, were
considered good and sufficient industrial
hygiene practice to mitigate development of
sensitization and disease. However, over the
last decade, the rates of sensitization and dis-
ease did not decline. Because the most com-
mon worker exposure is to the particulate
BeO, we investigated cutaneous exposure to
particulates as a potential route for sensitization
to beryllium. The data presented in this study
demonstrate that, in conjunction with motion,
fine particles penetrate the stratum corneum
and lodge in the epidermis, the anatomical
location of the cutaneous antigen-presenting
cell, the Langerhans cell. Further, we provided
evidence for a murine beryllium-speciﬁc, cell-
mediated immune response following cuta-
neous application of BeO and BeSO4.
Activation of cutaneous immunity by per-
cutaneous absorption of chemical through the
stratum corneum is well established; however,
given the long dissolution half-life for beryl-
lium metal and its alloys, we hypothesized that
beryllium particles would have to colocalize
with the cutaneous antigen-presenting cell in
the epidermis in order to activate a cell-medi-
ated immune response. To reach the epider-
mis, particles would have to traverse the
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Figure 3. Scanning electron microscopic images of
the surface of skin samples tape stripped 0 (A), 10
(B), and 20 (C) times. Skin treated with 1-µm beads
was flexed for 60 min, rinsed, and subjected to
repeated applications of D-Squame tape as
described in “Materials and Methods.” The red
boxes indicate location of beads. 
Figure 4. Lymphocyte proliferation measured by
3H-thymidine incorporation in auricular LN cell
preparations derived from (A) AOO-treated mice
and (B) BeSO4-treated mice. Single-cell suspen-
sions of auricular LNs were prepared and stimu-
lated as described in “Materials and Methods” and
harvested at the designated time points. No BeSO4-
stimulated cell proliferation was measured in LN
cells obtained from AOO-treated mice. Data are
presented as the mean ± SEM and are representa-
tive of three experiments; n = 10 mice per group.
Figure 5. Lymphocyte proliferation measured by
3H-thymidine incorporation in PBMC preparations
derived from (A) AOO-treated mice and (B) BeSO4-
treated mice. PBMCs were isolated and stimulated
as described in “Materials and Methods” and har-
vested at the designated time points. No BeSO4-
stimulated cell proliferation was measured in
PBMCs obtained from AOO-treated mice. Data are
presented as the mean ± SEM and are representa-
tive of ﬁve experiments; n = 10 mice per group.
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Article | Tinkle et al.stratum corneum. The stratum corneum is
composed of several layers of randomly
stacked corneocytes surrounded by lipids. The
lipids are arranged in overlapping lamellar
sheets and form pathways for molecular trans-
port into and through the stratum corneum.
These channels follow a winding but continu-
ous path from the surface of the skin into the
epidermis (Menon and Elias 1997). Our data
demonstrate the passage of fluorospheres,
≤ 1 µm, through stratum corneum, into the
epidermis. Although we are unable to demon-
strate deﬁnitively that the particles are within
these intercellular pathways, it is reasonable to
consider that these lipids would be sufﬁciently
malleable that fine particles, in conjunction
with motion, could enter. Lacunae, or bulges,
identiﬁed in these lipid pathways may explain
the occasional clustering of ﬂuorescent beads
that we observed. Once in these lipid chan-
nels, over time particles could continue to
move into the skin and be phagocytosed by
the Langerhans cells. Murine Langerhans cell
phagocytosis of  0.5–3.5-µm microspheres has
been demonstrated in vitro by Reis e Sousa et
al. (1993). These data provide the link
between our proof of concept experiments for
particle entry into the stratum corneum and
BeO-stimulated skin sensitization.
The application of external force is a
consistent component of particle penetration
studies. Lademann et al. (1999) and Tan et
al. (1996) documented titanium dioxide
penetration of the stratum corneum following
repeated rubbing of sunscreen onto the volar
forearm. The podoconiosis literature ascribes
development of disease to soil microparticles
driven through the soles of the feet. Individuals
walked barefoot, and over time, microparticles,
frequently 0.4–0.5 µm but as large as 25 µm,
were observed in the femoral and inguinal LNs
by scanning electron microscopy (Blundell et
al. 1989; Corachan et al. 1988). In our experi-
mental system, we employed ﬂexing motion,
as at the wrist, as the external force, and
observed no particle penetration in its absence.
The differences in particle size in these studies
may reﬂect the difference in the magnitude of
the force applied and perhaps the lipid com-
position of the skin area.
We also documented a particle size cutoff
in our ex vivo system, at a diameter of 1 µm.
Other researchers tested particle penetration of
the skin using particles with diameters of
≥ 3–8 µm (Andersson et al. 2002; Lademann
et al. 1999, 2001). These studies identified
clusters of particles on the surface of the skin,
at the hair follicle oriﬁce, or within the follicle,
but no documentation of particles in the epi-
dermis. These data are consistent with our 1-
µm size cutoff and may explain others’ inability
to make observations similar to our ﬁndings.
We have shown that cutaneous applica-
tion of beryllium induces a beryllium-speciﬁc
murine DTH. Historical studies from the
1950s–1980s used intradermal injection or
epicutaneous beryllium solutions to evaluate
a diagnostic skin patch test and to demon-
strate the immunologic underpinnings of the
beryllium cellular response. Beryllium salts,
especially beryllium fluoride, cause a dose-
related erythema and edema, and although
there are several clinical reports of beryllium-
induced contact dermatitis (Curtis 1951), a
strong association between skin rash and the
development of sensitization and disease was
not observed. Belman (1969) documented
preferential sequestration of topically applied
beryllium ﬂuoride in guinea pig epidermis and
increased beryllium binding afﬁnity for dena-
tured proteins. Reeves and Krivanek (1974)
concluded that biweekly intradermal injection
of beryllium salts into guinea pig abdominal
skin for 6 weeks conferred resistance to pul-
monary sensitization. This repeated exposure
treatment paradigm is consistent with studies
on cutaneous induction of tolerance, not sen-
sitization; however, extrapolation of the ﬁnd-
ings to human exposure was not explored. 
Several studies demonstrated that the
murine beryllium-MHC class II restriction is
Iak (Huang et al. 1992), the isoform present in
C3H mice, and conceptually analogous to the
human beryllium HLA-DPB restriction iden-
tiﬁed by Richeldi et al. (1993) and Wang et al.
(1999, 2001). Using ﬂow cytometry and the
BeLPT, we demonstrated that the murine
response to topical beryllium occurs in the LN
draining the site of chemical application, the
auricular LN in our study, and that T cells are
activated and released into the peripheral
blood. Using a classical measure of skin sensi-
tization, we have shown elicitation of the ear-
swelling response in BeO-sensitized mice. In a
pilot study, we removed excess BeO from the
surface of the ﬂank skin immediately follow-
ing the 24-hr exposure by gentle washing and
tape stripping three times. On day 7 or 14 fol-
lowing the exposure, the amount of beryllium
in the ﬂank skin of BeO-treated mice was, on
average, 1.2 µg/g tissue, thus conﬁrming that
BeO is present in the skin (data not shown).
Interestingly, application of BeO produced no
erythema or edema in the sensitized mice.
Shaved ﬂank skin maintained a normal color
and appearance following topical application
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Figure 6. T-Lymphocyte activation induced by topically applied BeSO4 (A) and BeO (B). BeSO4 (n = 5 mice),
DNFB (positive control; n = 2 mice), DBPT (vehicle; n = 2 mice), or BeO (n = 5 mice) was applied to the dor-
sum of the ear; single-cell suspensions of auricular LNs were prepared; and the percentage of LN cells
expressing CD44 and CD62L was analyzed by ﬂow cytometry 48 hr later (see “Materials and Methods” for
details). In (B), BeO induction of T-cell activation was evaluated in a sensitization–challenge paradigm as
described in “Materials and Methods.” The increase in CD44 and the decrease in CD62L was measured
only on cells obtained from BeO-sensitized mice. Data are presented as the mean ± SEM and are repre-
sentative of three experiments.
*Signiﬁcant increase with respect to vehicle-treated mice. **Signiﬁcant decrease with respect to vehicle-treated mice.
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Figure 7. Elicitation of an ear-swelling response fol-
lowing sensitization by topical application of BeSO4
or BeO. Mice were sensitized with BeSO4 or
BeO/petrolatum and challenged on the ears 1 week
later as described in “Materials and Methods.” Mice
sensitized with BeSO4 or BeO displayed a signiﬁcant
increase in ear thickness following challenge on the
ear with BeSO4. Data are presented as the mean ±
SEM and are representative of  three experiments.
*Signiﬁcant increase with respect to control mice. 
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of BeO or following intradermal injection,
and within days, hair growth was evident.
The formation of noncaseating granulomas
in beryllium disease occurs primarily in the
lung, and skin exposure to beryllium particu-
lates had not been considered hazardous to the
workers. We have demonstrated that BeO ini-
tiates cutaneous sensitization in mice and have
provided proof of concept experiments for ﬁne
particle penetration of skin as an initiating
event in this process. Because the concentra-
tion of antigen required for elicitation of a
cell-mediated immune response is signiﬁcantly
smaller than the concentration required for
sensitization, our data may provide insight
into the immunopathology underlying the
failure of respiratory exposure limits to lower
the rate of disease over the last decade. Our
ﬁndings suggest that, for workers with signiﬁ-
cant beryllium skin exposure, the pulmonary
exposure required to elicit a subsequent
immune response and granuloma formation
would be significantly smaller. We are cur-
rently characterizing the murine peripheral
immune response to beryllium and investigat-
ing the relationship between skin sensitization
and pulmonary disease. Although these studies
were performed in the context of beryllium
disease, evaluation of cutaneous particle expo-
sures in other occupational settings may be
warranted.
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